Pfizer Inc. (NYSE:PFE)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for PFE
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- DavidG: $PFE Has been in a 1 month tight base with tight BB squeeze of 2.9%. Today it is breaking out on good volume. Long from 28.5 in my IRA for the 5.7% dividend. Also long the Oct $29 calls which finally are in the green for me.
- phgruver: Healthcare $XLV, and utilities, $XLU are my best performers, so far today. In healthcare I have $ABBV, $BMY, $CVS and $PFE. I would suggest you stay away from $PFE, but the others are cooking! In utilities I have $AEP, $D, $DUK and $SO. I'm not real happy with $D, but the others all have nice charts and pay decent dividends. $AEP, $DUK and $SO are all breaking out from a squeeze and are above the upper Bollinger Band.
- woodman: @phgruver $XLV $XLU $ABBV $BMY $CVS $PFE $AEP $D $DUK $SO - Some additional sectors, perhaps: XLRE, SDY, maybe IHI (but nearing rising resistance), and maybe XLF & GLD/IAU (they are resting today)
- DavidG: @phgruver $PFE Would like to know your thoughts on $PFE. I see it squeezing at 3% BB width, right at the 20d and 50d EMA. Fairly easy to define your risk. Still would appreciated any thoughts you have.
- phgruver: @DavidG $PFE Man, I could write a whole blog post about that! Let me try to put it succintly, though. First, $PFE is an established player in a difficult sector with a wide moat to their business. The FDA is a major obstacle to any newcomer! So, ...
- jaeran: @woodman $XLV $XLU $ABBV $BMY $CVS $PFE $AEP $D $DUK $SO
- DavidG: @DrScience $PFE $INTC I think the lack of influenza B titers in the phase 2 trial is a minor issue because influenza B is relatively rare in the US compared to Influenza A. I believe today's drop in the $PFE stock is an over- reaction to the repo ...
- kingtug13: $PFE - nice bounce off the 200ma!
- kingtug13:
- kingtug13: Currently long $TSLA $HD $IBIT $PFE and short $SBUX. tight stops.
- kingtug13: $PFE BOUNCING OFF 200MA
- wijimmy: $PFE ... WEIRD DAY .... just noticed STOPPED OUT of $PFE ... and ... Daiwa Securities Upgrades Pfizer TODAY to Outperform From Neutral, Adjusts Price Target to $34 From $28
- mopick: @wijimmy $PFE, what a colossal dog this stock has been! Pull up a 10 yr chart and it's hovering close to the bottom. Gets that upgrade in a big up market & the stock is down? WFT? Holding a small amount, yield play 5.8%
-
StockMarketMentor: ...
Currently $ABBV is the only one that’s active ($PFE got stopped out yesterday for a small loss). I will likely put a few stocks on today to capitalize on any continuation of yesterday’s buying.
Watch for it on Telegram, in the Tradin ... - Henry: $PFE perky out of the gate
- Henry: $PFE $LLY Lilly, pin action off PFE's earnings
- phgruver: It's a little harder to find info on Schwab than it was on TDA, but, $PFE reported 2nd qtr results, this morning (I think). They reported an EPS of $0.60/share, vs expectations of $0.46, on revenue of $13.28B, vs expectations of $13.02B. A nice beat on both metrics. In addition, $PFE raised full year guidance. The market's reaction, so far, has been under-welming, but they did have a decent run up into earnings, so this isn't unexpected. The stock should find support between $29.50 and $30. Wait for a green day to add. The 200dma, while flattening, is still in a downtrend.
- DavidG: $PFE Started a 1/3 position @ $30.07 and also sold 16Aug $30 puts. Earnings showed significant beat and they raised estimates, so the pullback seemed like an opportunity to pick this up. I was following a 2 min chart and executed the trades when price started to curl up.
- Max115: $PFE reports 7/30
-
StockMarketMentor: ...
$PFE: Short term extended, but the bullish crossover of the 50-day moving average and the 200-day moving average is a great sign of higher prices to come.
$PLTR: Working pretty well and on trend.
$WMB: Flat this morning after a breakout on Fri ... - joelsg1: @DAN $CRWD $LUV $PFE Plenty evidence Russians hacked the DNC 9 years ago using Putin's Bear Bros. Cozy and Fancy, no relation to the restaurant crew on the popular FX show. Endorsed by bipartisan Congressional Committees, and Trump's deflection it wasn't Russia but Ukraine thoroughly debunked. https://www.crowdstrike.com/blog/bears-midst-intrusion-democratic-national-committee/ https://www.washingtonpost.com/technology/2024/07/20/crowdstrike-conspiracy-theory-trump-russia-dnc/
-
StockMarketMentor: ...
COTD: Does your trading need a shot in the arm? Try Pfizer ($PFE). (Pun intended).
https://us02web.zoom.us/rec/share/9AXpaWvOgQarOu6hIxbAvAIrSyKuQ1Tf9QaRA_F0bBAFp_QaGIPbu8-OTCbrxbnH.fVJ65-Js4g_a7bpt
SS: Some thoughts and suggestions that wi ... - cgendro1: @StockMarketMentor $CRWD $LUV $PFE Elon Musk says he has removed CRWD from all his systems. Lots of interesting info re CRWD ownership and server locations :)
- DAN: @cgendro1 $CRWD $LUV $PFE Crowdstrike was the company that shilled for HRC back when the DNC's emails were downloaded on a local computer (rumored to have been taken by Seth Rich and given to wikileaks...but I have no insight into that). Crowdstrike "examined" the data and concluded (without any proof whatsoever) that the Russians had hacked the email. And thus...Russia, Russia, Russia was born. Anybody can think what they want about that stuff...but it happened.
- bigreek42: @DAN $CRWD $LUV $PFE similar to those 51 intelligence "experts" : )
- Rjeletrik: $PFE $29.55 what has been resistance is now support? Long
-
StockMarketMentor: ...
For possibilities in healthcare stocks, you can consider the Death Star Drug Store: Pfizer ($PFE). It’s breaking out of a base with a 50-day / 200-day moving average crossover. Earnings are due on July 30th. I’ll add this to the list i ... - wjj3: @StockMarketMentor $XLF $XLV $BAC $PFE $ABBV $JNJ $ $GEHC upward price action is
- DAN: $PFE is looking good this morning. The stock is coming out of a 7 month base, so my bet is that this continues to run.
- StockMarketMentor: $PFE broke through yesterday's intraday high and is now added to the ATI List. Basis 30.31 Stop 28.90 --Dan
- Aibistin-1: @DAN $PFE I took a position earlier @ $30.50. I intend holding based on its weekly chart.
- phgruver: As a long term hold, you can buy right here. This is near the bottom of it's range. As a speculative swing trade, not so much, it's already had a big-ish move, although it could move a lot more. Look at the weekly chart, it's just coming off the bottom. Major resistance around $30, and then again, some at $34, and bigger resistance at $38. Can it get back to $40? Sure, but not in a straight line. This stock pays a significant dividend, 5.5% at today's price. That dividend is big enough to attrract #VALUE investors. As long as health care doesn't become the political football of this election cycle, $PFE should do pretty well. I added a little to my existing $PFE position yesterday, at $29.90.
- MongosPawn: $PFE Trying to make a new 2024 high. Higher highs and higher lows recently. Trend change? Earnings in 2 weeks.
- phgruver: @MongosPawn $PFE They also pay a 5.6% dividend, at the current price. This is well covered by earnings, so that makes this a #VALUE play. Something to consider for a long term portfolio.
- DavidK: @phgruver $PFE #VALUE Josh Brown has been touting it for awhile . I am sure he will be back at it again on his next Halftime appearance.
- MongosPawn: @phgruver $PFE #VALUE Excellent point. Took a starter and have added during this consolidation period since seeing the post by @TraderGeekSam last March. Is a long term stock for me.
- DavidK: @traderbren $NDAQ Josh is back on the $PFE bandwagon again . I tried it a while back and got bucked off . He also was spewing how $IWM stocks would be making lots of profits . Not sure how he has that much insight . I did buy 10 $IWM calls yesterday for more than a double sold this am .
- woodman: $PFE $SRPT - Pfizer's DMD Phase 3 fail leaves SRPT (PDUFA 6/21) as the only game in town. https://www.fiercebiotech.com/biotech/pfizers-phase-3-gene-therapy-trial-fails-improve-function-boys-duchenne-muscular-dystrophy
- joelsg1: @woodman $PFE $SRPT Never liked $SRPT on MD since it got the nod over $BMRN, word then was it was close but FDA approved $SRPT to give some hope to families affected by MD, not that their drug worked that well. Tough nut to crack.
- woodman: @joelsg1 $PFE $SRPT $BMRN - I have no skin in the DMD TA. I think it will be approved, but it may have a strict/limiting label. The testimony of parents whose kids have improved quite a bit is compelling.
- woodman: $PFE - Nearing the overhead 200d. It's had a definite change in complexion over the last almost 3 weeks.
- Motorman: @woodman $PFE Also 50Week. Starting a small position to add to as it gets through both.
- bwcarnation1: @Motorman $PFE I did the same
- mopick: @woodman $PFE Seagen purchase was a good one, should expand their oncology pipeline in the future.
- woodman: @mopick $PFE - It should buy or partner with $VKTX for an obesity play, in my humble opinion. :-)
- Geewhiz: @joelsg1 $NVDA 25B $GOOGL 12.4B : $PFE 5.7B: $MSFT 7.5B: $META 2.6B
- woodman: $PFE - continuing the discussion from earlier about this move higher from massive pullback, PFE has announced a plan to cut even more costs. It had already started a $4B savings strategy. Now it is planning on a new $1.5B round of cost savings. The market must like it. https://www.msn.com/en-us/money/companies/pfizer-plans-to-cut-costs-by-15-billion-as-demand-for-covid-vaccine-dwindles/ar-BB1mSieQ?ocid=BingNewsSerp
- joelsg1: @Geewhiz $NVDA $GOOGL $PFE $MSFT $META We'll have to rethink what constitutes a "big" move.
-
StockMarketMentor: ...
I think this is a pretty interesting market because of the relatively low barrier to entry. There isn't just one patent such as the situation with Pfizer ($PFE) back in the day when the little blue pill was completely owned by Pfizer. Here, there ... - joelsg1: @woodman $VKTX $PFE $MRK $JNJ $REGN $RHHBY (Roche) in the game as well with early results this am.
- Bs7518: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for sharing its helps me stay clear on what i'm doing. You ROCK:)
- woodman: $PFE change of complexion.
- joelsg1: @woodman $PFE Rosacea? :)
- SusanW: @woodman $PFE I have bought and sold PFE and made money. I am now in again hoping the $SGEN combination takes off.
- woodman: @SusanW $PFE $SGEN - I'm *hoping* PFE enters into a collaboration/agreement with (if not a buyout of) $VKTX for the obesity drug. But the $43 billion buyout of SGEN is a big weight on PFE's books and could limit PFE's ability to do other big deals. That's why a parternship of some sort may be more palatable for PFE since buying VKTX may be more than it would want to spend now. But I think there are multiple potential suitors for VKTX.
-
woodman: ...
All this speculation wouldn't be complete without speculating about who would buy or partner with VKTX. Many have speculated $PFE. I don't think so because it still has to digest all that SGEN debt on the books, and there are other BPs with more ... - Geewhiz: @woodman $VKTX $PFE $MRK $JNJ $REGN Thank you for these thoughts. Holding $ARDX and $VKTX since you first mentioned. Much appreciated and much appreciate your sharing. Pardon that pun! ;-)
- DavidK: @Lou $CLSK $VKTX $DBRG $FTI $EPD I am positioning to some selling next week . Money managers gonna hold thru end of quarter and then sell some next week or so . I am only long $CLL ( small ) $PFE calls medium , small $ TLRY . Long VXX calls
- champ: @DavidK $CLSK $VKTX $DBRG $FTI $EPD $CLL $PFE ....The way that it normally works is....money managers don't sell in a strong Market...plus they will hold into the first earnings reports from the Banks...and that starts on 4/12...... ....plus they are not going to miss a strong earnings season, they will at least wait to see how earnings reports go..... however small traders might move off...but Not the money managers, thats my guess.
- DavidK: @champ $CLSK $VKTX $DBRG $FTI $EPD $CLL $PFE good catch . I did forget about this being an earnings report month . Probably small fry’s like me selling some stuff . I don’t like to hold thru earnings unless I really feel confident. $CCL I had a big call position about 2-3 days before earnings but bailed . I didn’t like price action
- Cheezit: @DAN Hi Dan $CART $PFE $TOST Please and Thank You..
- DavidK: $PFE - sold earlier today for 53% 1 week gain on calls . Up another 10% from my sell point . Does it stall here or go to 30 ? Josh Brown has been buying for a couple weeks and now he might be about even .
- DavidK: $PFE - Josh Brown was touting this yesterday ( actually the last few weeks ) and then another analyst later in the day. I bought 20 Sept 27.50 calls yesterday .
- phgruver: @TraderGeekSam $PFE Your post got me looking at $PFE again. I've been very disappointed that they haven't bottomed out, yet. Like you, I don't think $PFE is going out of business. While I agree with others that the COVID vaccines and boosters were poorly handled, to say the least, $PFE has a lot more than that in their warehouse. With a dividend of 6.49%, they are worth considering in a long term portfolio. A note of caution, though. For the last 2 qtrs, earnings did not cover the dividend, although for the full year, they are OK. That said, I did add a bit more to my holdings at $25.80.
- TraderGeekSam: $PFE trades like it's going out of business, but it's not. The pipeline is brewing with opportunities, and although it's is in a steep downtrend, at $25.85, this very cheap pharma stock is ripe for at least a robust countertrend bounce. As a portfoli ...
- woodman: @TraderGeekSam $PFE - Can it spare $30B for $VKTX? :-)
- DavidK: @woodman $PFE $VKTX not a bad idea . Looks like thier only hope near term is for them to team up with the govt and run another Covid lockdown .
- bigbartabs: @TraderGeekSam $PFE ... the chart looks like blood pouring out of a broken heart.
- Margi1983: $PFE. This massive Pharma company reached a low today not seen since 2013. They still have very high gross margin, but awful sales contraction and earnings reductions. At some point $PFE with a 6% divi will be a buy, possible a great LT investment. Maybe at 22. Thoughts??
- sierramp: @Margi1983 $PFE I wouldn't touch it until the 8D, 21D and 50D are in the right order.
- TraderGeekSam: @woodman $PFE $VKTX I doubt it. The acquisition of Seattle Genetics might have left the kitty a little bare. :-)
- TraderGeekSam: @Margi1983 $PFE See my earlier post about buying a chunk of PFE for my clients and myself today. This is a long-term position, not a trading position. I'm oftentimes early, but usually right when I've been this patient. I did the same with $TGT, $DELL, $STX, $WDC and many others that were being some like they were going out of business. PFE has a solid future.
- woodman: @DavidK $VKTX $LLY - I think they all do to some extent. I don't know how it compares. Don't over think it. Obesity is a HUGE Total Addressable Market. $100B or more annually by 2030. Most of LLY's $760B market cap is due to its obesity/diabetes med ...
- woodman: @RD $LLY - "Overweight" (haha). It has the best obesity med on the market. $VKTX will get a piece of that pie with one that is as good or better and that is safer. But I don't think VKTX will be around to market it itself. I think a BP competetor like $PFE will snap VKTX up eventually. I could see it happening this year. There's "room" for both in the portfolio. I have both.
- woodman: $VKTX through $30, now through $31. Racing to Q1 data for oral obesity med (which isn't really my focus but certainly curious) and subcutaneous obesity (which is my focus). CEO was talking positively about a Phase 3 trial plan for subQ obesity med VK ...
- phgruver: @woodman $VKTX $LLY $NVO $PFE $AMGN You're loosing sight of the fact that this is primarily a treatment for Type-2 Diabetes. Currently, it has to be administered as a shot. If they can convert it to an effective pill, the market is huge! Weight loss is a bonus, but most Type-2 Diabetics are also overweight, so there's a lot of overlap. And, yes, you are correct, in order to bring it to market $VKTX will have to partner with, or sell out to a large pharma.
- woodman: $VKTX earnings/updates conference call 2/7 amc. https://ir.vikingtherapeutics.com/2024-01-31-Viking-Therapeutics-to-Report-Financial-Results-for-Fourth-Quarter-and-Year-End-2023-on-February-7,-2024 I have no idea if they will report any data at at that time. I've not seen any statements on that. All I have seen is that Phase 1 oral obesity drug data are expected 1Q24 and subq obesity drug data are expected 1H24. So any time, particularly for oral version. Manking things more interesting are buyout rumors, with $PFE's name being thrown around as a suitor. See https://seekingalpha.com/news/4060945-viking-therapeutics-gains-amid-takeover-speculation I'm not in this because I foresee an imminent buyout. I'm just letting things unfold with the data, etc. Eventually, if things keep going well, I expect a buyout, but imminently, who knows.
- DavidK: $PFE- my calls getting wacked . Thanks Josh Brown for steering me to this pos . Anyone have opinions on this chart . I had mine and so far wrong . I am like the fox who broke off the love affair with the skunk 🦨, he had not had all he wanted just all he could stand .
- woodman: $VKTX broke out last week, then sideways last few days. Now making a little flag. It is extended from the 50d and 200d with the 50 going to cross above the 200d soon. Shorter term, the 8dEMA has caught up again. It has oral and subq obesity drug cand ...
- bigbartabs: @DavidK $PFE ... I would sell and wait for it to recover the 20dma, and the 8dema.
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE You are kinda the expert around here :)
- joelsg1: @DavidK $PFE Don't buy anything pitched on tv, at least not immediately. There is always a reason why the producers decide to show it to you. Doesn't make them crooks, just reality. On chart, the adage applies: 'Nothing good happens under the 200d'.
- phgruver: @DavidK $PFE As a short term trade or swing trade, I think there are better candidates. As a long term, income producing hold, $PFE still looks pretty good. The yield is up to 5.85%. The recent low was $25.76, but you don't want to give it that much space. As long as it holds above $28, I think you can own it.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE https://i.gifer.com/1VF5.gif
- DavidK: @bigbartabs $PFE just sold before I saw your post . Thanks bought more $ TLRY. These pot stocks ($TLRY actually has lots of alcohol brands ) are spring loaded . There seems to be some encouraging developments regarding govt release of some studies . I like Tilray ceo as well . Good track record
- DavidK: @phgruver $PFE I had March calls that’s why I didn’t want to hold much longer . I usually don’t buy based on Tv touts but when I looked at the chart I thought it might be a candidate for a bounce and I quick trade.
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE More hair than I'd imagine.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE - Am I not using my nose-hair scissors (that I told @bigbartabs about) enough?
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- DavidK: $PFE- well it’s down $1 since Josh Brown recommended it a few days ago . I have March 29 calls . Might add around this level . On anther note , no way Fed drops rates anytime soon unless it’s in the Tank for Biden trying to juice markets even more . They didn’t work this hard trying to tame inflation to just drop rates .
- DavidK: $PFE - Josh Brown buying based on change in technicals . He went Thru a lot of reasons . I bought some March Calls . I don’t like the company and CEO at all but might be some Money to be made short term .
- Margi1983: @woodman $CLRB Thanks for the update. Long with modest position. You really know your biotech stuff. These others are not really biotech but I am also long $VRTX, $LLY, $NVO, and $PFE in the pharma space
- woodman: @Margi1983 $CLRB $VRTX $LLY $NVO $PFE - I won't hold all my shares through, but I still need to decide how much I will hold through. It's risky for sure. I can't imagine the company would be promoting this data so much into the presentation(s), but crazy stuff happens in BioLand. It could be a disappointment even if "good" or just simply an immediate sell the news. One never knows.
- camaro69: @phgruver $PFE $XLV Thanks for your post! This has been an easy one to hold since you posted
- Onthemark: $PFE breaking above 50d, would wait for pullback. Don't trust breakouts, better to buy bounces.
- Wolf: @Onthemark $PFE $ABBV is breaking out as well. Tagged the upper BB on decent volume. No position.
- Margi1983: $PFE reached a 10 year weekly low of $25.76 on 12/12/23. For my #LTInvestment account, I went long that day at 26.32. Now moving above the 50 ma today which is 29.47. Has 5.8% divi. This is LT value play. Revenue guidance for 2024 is quite flat, but EPS are expected to increase by 24% ( EPS from 1.45 -1.65 in 23 to 2.05-2.25 in 2024). $PFE needs to hold the 50 ma. Guidance for 2024 link here https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2024-guidance
- DavidK: @Margi1983 $PFE #LTInvestment well it is an election year and another pandemic could be brewing up just in time for another mandated school closings , business shutdowns , vote from home and another vaccine from Pfizer that doesn’t work as advertised .
- woodman: @DavidK $PFE #LTInvestment - It "advertised" that it would help people stay out of the hospital and stay off a ventilator or die. It never "advertised" that it would make one immune and not catch covid-19. It has worked as "advertised." I was vaxed multiple times. I've caught covid twice. I hardly had any noticeable symptoms. I know folks who weren't vaxed and became very sick. Anedotal, in my case, but true to the "advertising."
- woodman: $PFE #LTInvestment And I know someone who was reasonably healthy, as far as I know, but he refused to get vaccinated. He caught covid-19 and died and left a family behind. Very sad.
| Stock Price | $26.36 |
| Change | 2.29% |
| Volume | 116,185,000 |
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.
Request Video of PFEAlready a member? Sign in here.
Past Month
Leading Peers
-
$20.23 36.81%
-
$22.09 25.84%
-
$5.07 11.93%
Past Month
Lagging Peers
-
$6.48 -27.02%
-
$34.22 -24.89%
-
$10.89 -18.02%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!